



Published in final edited form as:

*Cancer Prev Res (Phila)*. 2020 September ; 13(9): 721–734. doi:10.1158/1940-6207.CAPR-20-0259.

## A comprehensive review and perspective on anticancer mechanisms of withaferin A in breast cancer

Eun-Ryeong Hahm<sup>1</sup>, Su-Hyeong Kim<sup>2</sup>, Krishna B. Singh<sup>1</sup>, Kamayani Singh<sup>2</sup>, Shivendra V. Singh<sup>1,2</sup>

<sup>1</sup>Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

<sup>2</sup>UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

### Abstract

Withaferin A (hereafter abbreviated as WA) is a promising anticancer steroidal lactone abundant in a medicinal plant (*Withania somnifera*) native to Asia. The root/leaf extract of *Withania somnifera*, which belongs to the *Solanaceae* family, continues to be included in the Ayurvedic medicine formulations of alternative medicine practice. Numerous chemicals are detectable in the root/leaf extract of *Withania somnifera* [e.g., withanolides (WA, withanone, withanolide A, etc.), alkaloids, sitoindosides, etc.] but the anticancer effect of this medicinal plant is largely attributed to WA. Anticancer effect of WA was initially reported in the early seventies in the Ehrlich ascites tumor cell model *in vitro*. Since then, numerous preclinical studies have been performed using cellular and animal models of different cancers including breast cancer to determine cancer therapeutic and chemopreventive effects of WA. Chemoprevention, a word first introduced by Dr. Michael B. Sporn, was intended to impede, arrest or reverse carcinogenesis at its earliest stages with pharmacological agents. This review succinctly summarizes the published findings on anticancer pharmacology of WA in breast cancer focusing on pharmacokinetic behavior, *in vivo* efficacy data in preclinical models in a therapeutic and chemoprevention settings, and its known effects on cancer-relevant cellular processes (e.g., growth arrest, apoptosis induction, autophagy, metabolic adaptation, immune function, etc.) and molecular targets (e.g., suppression of oncogenes such as estrogen receptor- $\alpha$ , signal transducer and activator of transcription 3, etc.). Potential gaps in knowledge as well as future research directions essential for clinical development of WA for chemoprevention and/or treatment of breast cancer also discussed.

### Keywords

*Withania somnifera*; Withaferin A; Breast Cancer; Chemoprevention

**Correspondence to:** Shivendra V. Singh, 2.32A Hillman Cancer Center Research Pavilion, UPMC Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15213. Phone: 412-623-3263; Fax: 412-623-7828; singhs@upmc.edu.

**Conflict:** The authors do not declare any conflict of interest.

## Introduction

Breast cancer is a serious health problem affecting hundreds of thousands of women worldwide. In the United States alone, more than 40,000 women are expected to lose battle to breast cancer in the 2020 (1). Novel therapeutic and preventative strategies are still needed to decrease the mortality and suffering from this disease. Extracts of medicinal plants or their small molecule constituents continue to be investigated as novel strategies for therapy and/or chemoprevention of breast cancer. *Withania somnifera* (also known as Indian winter cherry or Ashwagandha) belonging to the *Solanaceae* family of plants is an appealing medicinal plant under intense investigation for its effect on cancer and other ailments. The root/leaf extract of *Withania somnifera* continues to be included in formulations of Ayurveda, Siddha and Unani medicine practices in India and surrounding countries (2–7). More than 15 clinical trials using *Withania somnifera* extract are listed on the [ClinicalTrials.gov](https://clinicaltrials.gov) for different conditions. Clinical effects of *Withania somnifera* extract have been studied for management of male reproductive functions, neuroprotective potential, relief from stress and anxiety, improvement of memory and cognitive functions, muscle strength and recovery, etc. (8–11). *Withania somnifera* extract is available over the counter in the United States as a dietary supplement.

The phytochemical composition of *Withania somnifera* extract is quite diverse as illustrated by existence of withanolides, alkaloids, and sitoindosides (2). The anticancer potency of every identified chemical component of *Withania somnifera* extract is yet to be determined but withaferin A (WA; structure is shown in Figure 1A), a member of the withanolide family, has been studied most extensively for anticancer effect in different cancers including breast cancer (12–18). This review summarizes the robust literature on anticancer effects of WA and its pharmacology focusing on pharmacokinetic behavior, *in vivo* efficacy data in preclinical rodent models of breast cancer, and its known effects on cancer-relevant cellular processes (e.g., cell cycle arrest, induction of apoptosis and autophagy, metabolic adaptation, and immune function) and molecular targets (e.g., suppression of estrogen receptor- $\alpha$ , signal transducer and activator of transcription 3, etc.). Gaps in knowledge as well as future research directions to facilitate clinical development of WA for chemoprevention and/or treatment of breast cancer are also discussed.

## Pharmacokinetic behavior of WA

Knowledge of the pharmacokinetic behavior of an agent is of paramount importance for its clinical development. This information is critical not only for *in vitro* mechanistic studies (e.g., dose selection based on maximum plasma/serum achievable level to avoid use of supra-pharmacological concentrations) but also for dosing schedule in preclinical and clinical studies based on half-life and tissue availability and clearance. Data on pharmacokinetic behavior of WA in rodents are summarized in Table 1. In female Balb/c mice, a single intraperitoneal injection of WA at a dose of 4 mg/kg body weight resulted in maximum plasma concentration ( $C_{\max}$ ) of about 1.8  $\mu\text{mol/L}$  with half-life of about 1.3 hours (18). An exposure area under the curve value ( $\text{AUC}_{0-1}$ ) of 1.09  $\mu\text{mol/L} / \text{hour}$  was estimated from this study (18). These results were obtained using reverse phase liquid chromatography-tandem mass spectrometry (LC/MS/MS) (18). In another study using

LC/MS/MS, pharmacokinetic parameters for WA were determined after oral administration of aqueous extract of *Withania somnifera* root to female Swiss albino mice at a dose of 1000 mg/kg [19]. The  $C_{\max}$  of WA was found to be lower [ $16.7 \pm 4$  ng/mL with observed  $T_{\max}$  (time to reach  $C_{\max}$ ) of 20 minutes] (19) than that observed after intraperitoneal injection (18). Lower plasma level of WA from oral administration of the aqueous *Withania somnifera* extract is understandable because WA is a hydrophobic molecule and hence water is not the best solvent for its extraction. Our laboratory was the first to demonstrate mammary tumor tissue bioavailability of WA after cumulative intraperitoneal injections of 4 mg/kg or 8 mg/kg body weight (five times/week for 10 weeks) by using LC/MS/MS (20). The mammary tumors in this study were induced by a single intraperitoneal injection of the carcinogen *N*-methyl-*N*-nitrosourea (MNU) to female Sprague-Dawley rats (20). The WA was also detectable in the rat plasma but this study was not designed to determine the pharmacokinetic parameters (20). More recently, two different groups of investigators have determined pharmacokinetics and oral bioavailability of WA in rats with widely differing conclusions (21,22). Both these studies utilized LC/MS/MS technique to measure WA levels (21,22). Dai et al (21) reported an oral bioavailability of about 20% based on WA measurement in the plasma of male Sprague-Dawley rats following oral and intravenous administrations of 10 mg/kg and 5 mg/kg, respectively (21). The  $C_{\max}$  for WA following intravenous and oral administrations were about 6.5 and 1.3  $\mu\text{mol/L}$ , respectively (21). In the other study, pharmacokinetic parameters of WA were determined in Sprague-Dawley rats (sex not specified) after a single intravenous administration of 4.5 mg/kg or a single oral treatment with 0.5 mg/kg, 1.5 mg/kg and 4.5 mg/kg (22). The oral bioavailability was found to be about 74% but the  $C_{\max}$  values were much lower ( $C_{\max}$  of 0.062  $\mu\text{mol/L}$  and 0.046  $\mu\text{mol/L}$ , respectively, after intravenous and oral administrations of 4.5 mg/kg than those reported by Dai et al (21,22). The half-life of WA was not affected by route of administration (22). However, much higher levels of WA were reported in tissues including stomach ( $\sim 5.7$   $\mu\text{mol/L}$ ), intestine ( $\sim 2.8$   $\mu\text{mol/L}$ ), heart ( $\sim 3.8$   $\mu\text{mol/L}$ ), liver ( $\sim 2.0$   $\mu\text{mol/L}$ ), lung ( $\sim 3.8$   $\mu\text{mol/L}$ ), kidney ( $\sim 3.6$   $\mu\text{mol/L}$ ), and spleen ( $\sim 2.1$   $\mu\text{mol/L}$ ) than in the plasma following a single oral administration of 4.5 mg/kg (22). The half-life of WA in tissues varied between 0.61 hours (spleen) and 3.21 hours (intestine) (22). The reasons for the discrepancy in results concerning oral bioavailability and  $C_{\max}$  values from the two rat studies are unclear and require further investigation. Finally, safety and pharmacokinetics of WA were determined in advanced stage high-grade osteosarcoma patients in a phase I clinical dose escalation study (classical 3 + 3 design in 10 male and 3 female patients) by using liquid chromatography. This study used the root extract of *Withania somnifera* standardized to contain 4.5% of WA (w/w) (23). The dosing regimen reflected daily WA intake of 72 mg, 108 mg, 144 mg, and 216 mg, respectively (23). The authors concluded that WA was well tolerated but it was not detectable in the plasma of any patient (23). However, additional pharmacokinetic studies with pure WA administration and use of more sensitive analytical techniques (LC/MS/MS) and determination of levels in tissue of interest may reveal whether the oral bioavailability of WA is really very low in humans compared to rodents.

## ***In Vivo* Studies on WA in preclinical models of breast cancer**

### **(A) Inhibitory effects of WA in a therapeutic setting**

The *in vivo* efficacy studies with WA in preclinical models of breast cancer in a therapy or chemoprevention setting are summarized in Table 2. The term chemoprevention was introduced by Dr. Michael B. Sporn signifying “use of pharmacological agents to impede, arrest or reverse carcinogenesis at its earliest stages with pharmacological agents” (24). This definition is now expanded to include natural or synthetic small molecules, dietary or medicinal plant extracts or biologics (vaccine) for chemoprevention of cancer. In a xenograft study, MDA-MB-231 cells were subcutaneously or orthotopically implanted in female athymic nude mice, and the mice were injected intraperitoneally with either vehicle (10% dimethyl sulfoxide, 40% cremophor-EL, and 50% phosphate-buffered saline) or the same vehicle containing 4 mg WA/kg body weight for 2.5 weeks (15). The average tumor volume in control mice was higher by ~1.8-fold compared with WA-treated mice ( $P < 0.05$ ) (15). In another study, the *in vivo* growth of subcutaneously injected MDA-MB-231 cells was inhibited by about 65% as reflected by tumor weight (25). The *in vivo* growth inhibitory effect of WA against genetically modified MDA-MB-231 cells with stable knockdown of the Notch2 protein was also demonstrated (26). Using orthotopic 4T1 mouse mammary cancer model, Thaiparambil *et al* (18) showed antitumor activity of WA at 2 mg/kg and 4 mg/kg doses administered by intraperitoneal injection every other day for 30 days. The *in vivo* efficacy of WA in MDA-MB-231 xenograft model was also demonstrated by Liu *et al.* (27).

Breast cancer is a heterogeneous disease that is broadly grouped into major subtypes including, luminal-type, basal-like, human epidermal growth factor 2 (HER2)-enriched, and normal-like (28). Therefore, the obvious gaps in knowledge regarding *in vivo* cancer therapeutic effects of WA include determination of: (a) whether oral administration of WA inhibits the growth of breast cancer cells, and (b) whether *in vivo* growth inhibitory effect of WA extends beyond basal-like MDA-MB-231 and 4T1 cells. Further research is necessary to systematically address these important questions.

### **(B) Inhibitory effects of WA in a chemoprevention setting**

Chemoprevention, especially using non-toxic phytochemicals from dietary or medicinal plants such as WA, represents a sensible strategy for decreasing the death and suffering from cancer including breast cancer. Breast cancer is one of the few malignancies for which clinically successful interventions for chemoprevention are available including selective estrogen receptor modulators like tamoxifen (Nolvadex<sup>®</sup>) and raloxifene (Evista<sup>®</sup>) and aromatase inhibitors such as exemestane (Aromasin<sup>®</sup>) for luminal-type subtype of the disease (29–31). However, a chemopreventive intervention for non-luminal-type breast cancers is still a clinically unmet need. Chemopreventive efficacy of WA has been demonstrated in rodent models representative of two different subtypes, including HER2-driven breast cancer in a mouse model (MMTV-*neu* transgenic mice) and luminal-type breast cancer induced by MNU, a chemical carcinogen (20,32). In both these models, WA was administered by intraperitoneal route (20,32). Nevertheless, WA administration significantly inhibited burden and/or incidence of breast cancer in both models (20,32). In the MMTV-*neu* model, the incidence and burden (macroscopic tumor weight or microscopic

tumor area) were scored in female mice after 28 weeks of treatment with 100 µg WA/mouse (about 4 mg/kg body weight for a 25g mouse), three times/week or vehicle (32). The overall incidence of mammary cancer was not affected by WA administration in the MMTV-*neu* mice (32). However, the mean tumor weight in the WA treatment group was lower by 50% in comparison with the control group with a *P* value of 0.03 by two-sided Student *t* test (32). Microscopic examination of the Hematoxylin & Eosin-stained mammary gland sections also showed a significant decrease in the area (burden) of ductal carcinoma *in situ* and papillary tumor lesions as well as invasive carcinoma in the WA group compared with the control group (32). The mean area of invasive carcinoma, for example, was lower by 95.14% in the WA treatment group compared with the control group (32).

The MNU-induced breast cancer in rats is a widely used model in cancer chemoprevention research. A single MNU injection causes highly reproducible breast tumor development with high incidence in female rats (33). The mammary tumors from this model share histological similarities with human disease (34). Moreover, the gene expression profiling of breast tumors from the MNU-rat model reveals significant molecular overlap with luminal-type human mammary cancers (35). Preclinical efficacy data using the MNU-rat model were critical for clinical development of tamoxifen and aromatase inhibitor like vorozole (36,37). We used this model to determine chemopreventive efficacy of WA (20). WA (4 mg/kg or 8 mg/kg body weight by intraperitoneal route) was administered five times/week for 10 weeks starting one week after MNU injection (20). WA administration resulted in a significant decrease in mammary tumor incidence at both doses (20). The tumor multiplicity (average number of tumors/rat) as well as tumor weight were also lower in the WA treatment group compared to vehicle-treated control rats (20). As an example, the wet tumor weight in the 8 mg/kg group was lower by about 68% when compared to control rats (20). Collectively, these studies provided preclinical evidence for chemoprevention of two different subtypes of breast cancer with WA administration (20,32). However, the chemopreventive efficacy of WA against basal-like breast cancers is yet to be determined.

### (C) Inhibitory effects of WA on breast cancer stem-like cells (bCSC) *in vivo*

The bCSCs, which were first identified by Al-Hajj and colleagues (38), are believed to be responsible not only for breast cancer initiation and progression but also for treatment failure (39,40). Therefore, it is only logical to develop strategies for elimination of both therapy-sensitive tumor cells constituting bulk of the tumor mass and bCSC to achieve maximal chemopreventive and therapeutic response. The bCSCs are characterized by their ability to form mammospheres and express high aldehyde dehydrogenase 1 (ALDH1) activity. Flow cytometric determination of CD44<sup>high</sup>/CD24<sup>low</sup>/epithelial-specific antigen-positive (ESA<sup>+</sup>) population is another technique for quantitation of bCSC fraction. A study from our laboratory showed that WA concentrations ranging from 0.25 to 1 µM significantly inhibited first- and second-generation mammosphere frequency, ALDH1 activity, and CD44<sup>high</sup>/CD24<sup>low</sup>/ESA<sup>+</sup> population in luminal-type (MCF-7) and triple-negative (SUM159) human breast cancer cell lines (41). We also used freshly harvested tumors from control and WA-treated MMTV-*neu* mice (0.1 mg WA by intraperitoneal route, 3 times/week) to demonstrate a 44% reduction in ALDH1 activity in tumors of WA-treated mice compared to control (41). The WA-mediated decrease in ALDH1 activity was also found in the MNU-rat tumors when

compared to control (20). However, it is still unknown if the bCSC fraction can be suppressed by oral administration of WA. Also, further studies are needed to determine if bCSC fraction in HER2-enriched cells like SK-BR-3 are sensitive to inhibition by WA.

#### (D) Inhibitory effects of WA on metastasis

The anti-metastatic effect of WA has been reported in mouse models. In one such study, pulmonary metastasis induced by orthotopic injection of 4T1 mouse mammary cancer cells in female Balb/C mice was inhibited significantly by intraperitoneal injection of WA every other day for 30 days (18). The anti-metastatic effect of WA was evident at a dose as low as 0.1 mg/kg body weight with about 30% reduction in the number of pulmonary metastatic nodules compared with vehicle-treated control mice (18). More than 70% decrease in pulmonary metastatic nodules was observed at the 4 mg WA/kg body weight (18). In another study, the same group of investigators demonstrated inhibition of pulmonary metastasis induced by mammary fat pad injection of 4T1 by oral administration of ethanol extract of *Withania somnifera* standardized for WA (1, 4, and 8 mg/kg body weight 3 times a week for 4 weeks) (42). Mice were also treated with WA (1, 4, and 8 mg/kg, intraperitoneal 3 times/week) to determine whether this small molecule is responsible for anti-metastatic effect of *Withania somnifera* (42). Both WA and the ethanol extract of *Withania somnifera* inhibited pulmonary metastasis multiplicity (42). The ethanol extract of *Withania somnifera* exhibited a slightly higher efficacy than WA but only at the 8 mg/kg dose (42). The MMTV-*neu* mice also develop spontaneous pulmonary metastasis. The incidence of pulmonary metastasis was decreased by about 73% upon intraperitoneal administration of 0.1 mg WA/mouse 3 times/week (32). Collectively, these studies demonstrated anti-pulmonary metastatic potential of WA.

Metastatic spread to distant organs is the primary cause of morbidity and mortality in subjects with breast cancer. Metastasis in breast cancer patients may be observed in the bone, lung, liver, and brain, but skeleton is the most preferred site for colonization in each subtype of the disease (ranges between 43 to 71%) when compared to other sites (8–47%) (43). In future, it would be worthwhile to determine whether the anti-metastatic activity of WA extends beyond pulmonary metastasis.

### Cancer-relevant cellular processes (cancer hallmarks) affected by WA treatment

The original six hallmarks of cancer included self-sufficiency in growth signals, insensitivity to anti-growth signals, tissue invasion and metastasis, limitless replicative potential, sustained angiogenesis, and evasion of apoptosis (44). This list has now been expanded to include new hallmarks like avoiding immune destruction, tumor promoting inflammation, genome instability and mutation, and deregulating cellular energetics (45). Studies have revealed inhibitory effect of WA on many of these cancer hallmarks in breast cancer as summarized in Figure 1A and briefly discussed below.

### (A) Inhibition of breast cancer proliferation and cell cycle arrest by WA treatment

Table 3 summarizes the results of cellular studies on biological effects of WA and includes information on cell lines and WA concentrations used for comparison. Cell viability inhibition by WA in cellular models of breast cancer was initially demonstrated by us using MCF-7 and MDA-MB-231 cells with an IC<sub>50</sub> between 1.5 and 2.0  $\mu$ mol/L following 24-hour treatment (15). Since then, several reports have not only confirmed our findings but also evaluated the anti-proliferative effect of WA in other breast cancer cell lines including 4T1 (basal), SUM159 (basal), SK-BR-3 (HER2-enriched), T47D (luminal A), Hs578T (basal), and BT474 (luminal B) (18,25,46–49). Estrogen-stimulated proliferation of MCF-7 cells was also inhibited significantly in the presence of WA (50). Anti-cancer effect of WA in the MDA-MB-231 xenograft model, but not in MMTV-*neu* or MNU-rat models, was associated with suppression of Ki-67 or PCNA expression (15,20,25,32).

WA treatment resulted in irreversible G<sub>2</sub>/M cell cycle arrest in MCF-7 and MDA-MB-231 cells that was accompanied by a decrease in levels of key cell cycle regulators, including cyclin-dependent kinase 1 (Cdk1), cell division cycle 25C (Cdc25C) and/or Cdc25B proteins leading to accumulation of tyrosine 15 phosphorylated (inactive) Cdk1 (51). Overexpression of the Cdc25C protein resulted in partial but statistically significant protection against WA-mediated G<sub>2</sub>/M phase cell cycle arrest in MDA-MB-231 cells (51). The G<sub>2</sub>/M arrest from WA treatment was confirmed by other investigators (52). Another study showed mitotic arrest following WA treatment in MCF-7, SUM159, and SK-BR-3 cells that was associated with a decrease in protein levels of  $\beta$ -tubulin (53). Naturally occurring C6, C7-epoxy analogs of WA (withanone and withanolide A) failed to cause mitotic arrest in these cells (53). The non-tumorigenic normal mammary epithelial cell line MCF-10A was more resistant to mitotic arrest by WA when compared to breast cancer cells showing cancer cell selective mitotic arrest by this agent (53). WA treatment also led to disruption of spindle morphology (53). Mechanism underlying G<sub>2</sub>/M arrest by WA seems complex and may involve additional regulators as demonstrated for peptidyl-prolyl *cis/trans* isomerase 1 (Pin1) (54). WA was shown to downregulate Pin1 and its ectopic expression attenuated G<sub>2</sub> and/or mitotic arrest resulting from WA in MCF-7 and SK-BR-3 cells (54). WA-induced apoptosis was increased by Pin1 overexpression in MCF-7 cells but not in the SK-BR-3 cell line. Furthermore, WA-mediated chemoprevention of breast cancer in MMTV-*neu* and MNU-rat models was associated with accumulation of mitotic cells as revealed by increased Ser10 phosphorylation of histone H3 *in vivo* (20). Collectively, these studies suggest that G<sub>2</sub>/M phase cell cycle arrest may be an important mechanism in antiproliferative effect of WA in human breast cancer cells (20,32,51–54).

### (B) Inhibition of angiogenesis, cell migration and invasion, and epithelial to mesenchymal transition (EMT) by WA treatment in breast cancer cells

Angiogenesis, cell migration and invasion, and EMT are critical steps in tumor metastasis (55–57). Published reports have established inhibitory effect of WA on all these pro-metastatic pathways. Thaiparambil *et al* (18) were the first to demonstrate inhibition of MDA-MB-231 cell invasion by *in vitro* wound healing and Matrigel invasion assays (18). Interestingly, inhibition of MDA-MB-231 cell migration in the presence of WA was evident at non-cytotoxic and non-apoptotic doses as low as 27 nM (18). Imaging studies revealed

promotion of perinuclear vimentin accumulation followed by rapid vimentin depolymerization after treatment with WA in breast cancer cells that was accompanied by Ser56 phosphorylation of vimentin (18). Vimentin protein is one of the critical proteins in EMT (56). In another study, WA treatment was shown to cause activation of Notch2 and Notch4 transcription factors but a decrease in levels of both transmembrane and cleaved form of Notch1 (58). Knockdown of both Notch2 and Notch4 in MDA-MB-231 and MDA-MB-468 cells augmented WA-mediated inhibition of cell migration (58). This study suggested an un-desirable effect where Notch2 and Notch4 activation impeded inhibitory effect of WA on breast cancer cell migration (58). A single-cell collagen invasion assay was also used to demonstrate inhibitory effect of WA on MDA-MB-231 cell invasion ability (47). Gene expression profiling in this study revealed a decrease in expression of several extracellular matrix-degrading proteases (uPA, PLAT, ADAM8), cell adhesion molecules (integrins, laminins), and certain pro-inflammatory mediators (TNFSF12, IL6, ANGPTL2, CSF1R) by WA treatment (47). It is still unknown if these gene expression changes affected by WA treatment are applicable to cell lines other than MDA-MB-231.

An experimental model of EMT following treatment of non-tumorigenic MCF-10A cells with tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and transforming growth factor- $\beta$ 1 (TGF- $\beta$ ) was used to demonstrate inhibitory effect of WA (59). Inhibition of experimental EMT and cell migration by WA treatment was partially reversed by combined TNF- $\alpha$  and TGF- $\beta$  treatments (59). Downregulation of E-cadherin is one of the hallmarks of EMT phenotype and breast cancer cells exposed to WA exhibited sustained (MCF-7) or transient (MDA-MB-231) induction of E-cadherin protein expression (56,59). Furthermore, the level of vimentin protein was significantly lower in the MDA-MB-231 xenografts and MMTV-*neu* tumors from WA-treated mice compared with corresponding controls (59). Finally, human umbilical vein endothelial cells were used to determine anti-angiogenic effect of WA (60). However, the number of CD31-positive blood vessels, a marker of neo-angiogenesis, was not significantly altered by WA administration *in vivo* in either MMTV-*neu* or MNU-rat models (20,32).

### (C) Modulation of DNA damage response by WA in breast cancer cells

Ataxia telangiectasia and Rad3-related (ATR)-checkpoint kinase 1 (CHK1) signaling plays an important role in the DNA damage response pathway for maintenance of the genomic integrity (61,62). The ATR kinase is activated by replication stress during cell division or genotoxic insult and functions at the S and G<sub>2</sub> phases of the cell cycle (61,62). Human breast cancer cells (MCF-7, MDA-MB-231, and SUM159) treated with WA showed suppression of protein level as well as phosphorylation of ATR and CHK1 due to both transcriptional and post-transcriptional mechanisms (63). Forced expression of CHK1 abolished the WA-mediated G<sub>2</sub>/M arrest but increased Ser10 phosphorylation of histone H3 (63). A trend for a decrease in the protein level of ATR was found in the mammary tumors of WA-treated MMTV-*neu* mice but the difference was not significant (63). A clinically relevant observation of this study was sensitization of MDA-MB-231 and SUM159 cells to growth inhibition by cisplatin but the *in vivo* effect of this potential combination regimen is yet to be determined (63). Additional studies are also needed to determine whether WA treatment affects other DNA damage response pathways.

#### (D) Induction of apoptosis by WA treatment in breast cancer cells

WA is best studied for its pro-apoptotic effect (18,25,27,52,64–70). We were the first to report apoptosis induction by WA in MCF-7 and MDA-MB-231 cells by western blotting for poly (ADP-ribose) polymerase cleavage and quantitation of DNA fragment release into the cytosol (15). The *in vivo* growth inhibition of MDA-MB-231 xenograft was accompanied by apoptosis induction as revealed by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay (15). The WA-mediated chemoprevention of breast cancer in both MMTV-*neu* and MNU-rat models was also associated with increased number of TUNEL-positive apoptotic cells (20,32). Since then, proapoptotic effect of WA has been confirmed by other investigators in cell lines other than MCF-7 and MDA-MB-231 (18,25,27,52,64–70). Mechanistically, generation of reactive oxygen species (ROS) is implicated in pro-apoptotic effect of WA (27,64). WA-mediated inhibition of oxidative phosphorylation (OXPHOS) at complex III of the mitochondrial electron transport chain was responsible for ROS generation (64). The ROS generation by WA is specific for cancer cells as this was observed in MDA-MB-231 and MCF-7 cells, but not in a normal human mammary epithelial cell line HMEC (64). The HMEC cells were also resistant to pro-apoptotic effect of WA (64). Overexpression of Cu, Zn-superoxide dismutase (SOD1) in MDA-MB-231 or MCF-7 cells or depletion of mitochondrial DNA (Rho-0 cells) also elicited resistance to WA-induced ROS production, collapse of mitochondrial membrane potential, and apoptosis (64). A critical role for ROS-dependent activation of Bax and/or Bak has also been suggested as a mechanism for WA-induced apoptosis (64). However, the mechanism by which WA inhibits complex III activity is still not completely understood although we have reported a decrease in assembly of complex III in MCF-7 and SUM159 cells but not in MDA-MB-231 after treatment with WA as determined by native blue gel electrophoresis (70). WA treatment also inhibited chemically induced mitochondrial fusion in breast cancer cells associated with downregulation of proteins involved in fusion process (mitofusin1, mitofusin2, and full-length optic atrophy protein 1; OPA1). The level of mitochondrial fission-regulating protein dynamin-related protein 1 (DRP1) was decreased by WA exposure and its deficiency as well as OPA1 knockdown attenuated apoptotic effect of WA (70). One study suggested induction of paraptosis, a form of cell death morphologically distinct from apoptosis or autophagy, by WA treatment (68) but the mechanism underlying this response or its *in vivo* relevance is yet to be determined.

#### (E) Inhibition of aerobic glycolysis by WA treatment in breast cancer cells

Metabolic reprogramming including increased glycolysis in tumor cells was added to the list of cancer hallmarks in the year 2011 even though this phenomenon was first described in the fifties by Dr. Otto Warburg (45,71). Normal cells derive ATP from OXPHOS whereas cancer cells become addicted to aerobic glycolysis to meet energy demand (71,72). Through unbiased global metabolomics, we reported a decrease in levels of several glycolysis and tricarboxylic acid cycle intermediates in the plasma and/or mammary tumor tissue of WA-treated MMTV-*neu* mice when compared to control mice (32). A cartoon summarizing WA-mediated suppression of the plasma and/or mammary tumor levels of glycolysis and tricarboxylic acid cycle intermediates (highlighted in red color) from MMTV-*neu* and MNU-rat models is shown in Figure 2. Expression of many enzyme proteins related to glycolysis and tricarboxylic acid cycle was also lower in the tumors of WA-treated MMTV-*neu* mice

than those of control mice (highlighted in green in Figure 2) (32). The WA-mediated suppression of glycolysis is not unique to the MMTV-*neu* model as a decrease in plasma lactate level was also observed in the MNU-rat model (20,32). Furthermore, WA administration resulted in suppression of glutamine and acetyl-CoA levels (20,32). Acetyl-CoA is the building block of fatty acid synthesis. Increased fatty acid synthesis or increased cholesterol uptake has been reported in HER2-enriched or triple-negative breast cancers (reviewed in 73). Thus, it is possible that WA treatment inhibits fatty acid synthesis in breast cancer cells, but additional work is necessary to test this hypothesis. In addition, the molecular basis for metabolic inhibition by WA is yet to be elucidated.

It is interesting to note that WA treatment inhibits OXPHOS in MCF-7 and MDA-MB-231 cells (64). Seahorse flux analysis revealed that basal oxygen consumption rate (OCR), which is a measure of OXPHOS, was relatively higher in the MCF-7 cell line when compared to MDA-MB-231 (64). However, both cells exhibited a statistically significant decrease in basal OCR following 4-hour exposure to 2.5 and 5  $\mu\text{mol/L}$  WA (64). The inhibitory effect of WA on basal OXPHOS was relatively more pronounced in the MDA-MB-231 cell line compared with MCF-7 (64). WA treatment resulted in a statistically significant decrease in reserve OXPHOS in MDA-MB-231 and MCF-7 cells especially at the 5  $\mu\text{mol/L}$  dose (64). However, it is unclear if WA treatment inhibits OXPHOS in HER2-enriched breast cancer cell lines *in vitro* or in breast cancer cells of different subtypes *in vivo*. We also know that WA targets complex III of the electron transport chain to disrupt electron flow that may explain the ROS production by this phytochemical.

#### (E) Immune modulatory effect of WA

Myeloid-derived suppressor cells (MDSC) play an important role in tumor promotion through inhibition of T cell function and crosstalk with tumor-associated macrophages (74). One of the mechanisms of evasion of tumor immunity by MDSC is the result of their crosstalk with tumor-associated macrophages for increased production of IL-10 (75). WA treatment was shown to inhibit MDSC and IL-10 production (76). Macrophages secrete IL-6 and TNF $\alpha$  that enhance accumulation and function of MDSC (74). Secretion of IL-6 and TNF $\alpha$  by macrophages was also inhibited by WA treatment (76). Oral administration of WA (1–8 mg/kg body weight, three times/week) to 4T1 mouse mammary tumor-bearing mice resulted in suppression of granulocytic MDSC (76). In another study, WA treatment inhibited mitogen-stimulated secretion of IL-2, IL-4, IL-6, and IFN- $\gamma$  in CD8 $^{+}$  and CD4 $^{+}$  T cells (77). Immune modulatory effects of *Withania somnifera* extract have also been reported that may be attributable to WA (78,79). However, the *in vivo* immune modulatory effects of WA in preclinical models of different subtypes of breast cancer are yet to be determined.

#### Molecular targets of WA in breast cancer cells

As described below and summarized in Figure 1B, WA targets multiple transcription factors, receptors, and kinases to elicit its anticancer responses, including apoptosis induction and inhibition of cell proliferation, cell migration/invasion and self-renewal of bCSC.

**(A) FOXO3a**

FOXO3a, a member of the forkhead box transcription factors, was the first identified mechanistic target of WA in breast cancer cells (15). FOXO3a is widely implicated in different solid tumors including breast cancer, and existing evidence indicates a tumor suppressor function for this transcription factor (80). FOXO3a knockdown in MCF-7 cells resulted in a partial but meaningful protection against WA-mediated apoptosis involving its downstream pro-apoptotic target Bim (15).

**(B) STAT3**

Overexpression and constitutive activation of STAT3 has been implicated in the progression, proliferation, metastasis, and chemoresistance of breast cancer (81). STAT3 is another transcription factor whose activity is suppressed by WA treatment in breast cancer cells (82). WA treatment was shown to inhibit constitutive and/or IL-6-inducible activation of STAT3 in MCF-7 and MDA-MB-231 cells as well as phosphorylation of its upstream regulator Janus-activated kinase 2 (82). Treatment of MDA-MB-231 or MCF-7 cells with WA also led to suppression of (a) transcriptional activity of STAT3 with or without IL-6 stimulation; (b) dimerization of STAT3 at least in MDA-MB-231 cells; and (c) nuclear translocation of phosphorylated STAT3 in both cells (82). The IL-6-mediated activation of STAT3 conferred a partial protection against cell invasion inhibition by WA in MDA-MB-231 cells (82).

**(C) ER $\alpha$** 

ER $\alpha$  is very well-studied for its pro-tumorigenic function in breast cancer (83). Growth inhibition and apoptosis induction by WA treatment in MCF-7 cells were significantly attenuated by ER $\alpha$  ligand 17 $\beta$ -estradiol (E2) (50). MCF-7 cells exposed to WA exhibited decreased protein levels of ER $\alpha$  (but not ER $\beta$ ) and ER $\alpha$  regulated gene product pS2, and this effect was also markedly attenuated by E2 (50). Overexpression of ER $\alpha$  in the MDA-MB-231 cell line conferred partial but statistically significant protection against WA-mediated apoptosis, but not the G<sub>2</sub>/M phase cell cycle arrest (50). Downregulation of ER $\alpha$  protein expression in MCF-7 cells following WA treatment was confirmed by another group of investigators (52).

**(D) p53**

p53, which is known to regulate cell cycle and apoptosis by different stimuli, is a well-known tumor suppressor (84). WA treatment caused induction as well as increased Ser15 phosphorylation of p53 (activation) in MCF-7 cells, although RNA interference of this tumor suppressor conferred only a modest protection against WA-induced apoptosis at least in this cell line (50).

**(E) Receptors and transcription factors linked to bCSC maintenance**

Expression profiling for stemness-related genes revealed (*Oct4*, *SOX-2*, and *Nanog*) suppression of only *SOX-2* mRNA after 24-hour WA treatment in MCF-7 cells and but downregulation of *Oct4*, *SOX-2*, and *Nanog* expression at the 72-hour time point in SUM159 cells (41). However, the precise function of these stemness-related genes in WA-mediated inhibition of bCSC is yet to be determined. Urokinase-type plasminogen activator

receptor (uPAR) overexpression alone is sufficient to drive stemness in MCF-7 cells (85). Overexpression of uPAR conferred partial but significant protection against bCSC inhibition by WA. Interestingly, WA treatment resulted in induction of Krüppel-like factor 4 (KLF4) expression, which was shown to be required for maintenance of bCSC and mammary cancer cell migration and invasion (86), in MCF-7 and SUM159 cells, and its knockdown by KLF4-targeted siRNA transfection augmented bCSC inhibition by WA (41). The Hedgehog pathway is implicated in hormone receptor positive and triple negative breast cancers (87). One study identified WA as an inhibitor of the Hedgehog pathway but experiments to determine the functional relevance of this finding were not conducted (88).

#### (F) Kinases

Effect of WA has been studied on extracellular signal-regulated kinases (ERK), p38 mitogen-activated kinase, and c-Jun N-terminal kinases (JNK) using breast cancer cells. All three kinases were activated by WA treatment in both cells (67). Overexpression of an anti-oxidative enzyme protein (manganese-superoxide dismutase) was partially protective against WA-mediated hyperphosphorylation (activation) of ERK, but not JNK or p38 MAPK (67). Apoptosis induction by WA treatment was significantly augmented by pharmacological inhibition of ERK and p38 MAPK in MCF-7 cells (67). On the other hand, WA-mediated apoptosis in MCF-7 cells was partially attenuated by JNK inhibition (67). Inhibition of ERK or JNK had no meaningful impact on WA-induced apoptosis in the SUM159 cell line. However, the effect of WA on these pathways in HER2-enriched breast cancer cells or normal mammary cells is yet to be determined. In another study, a rather high concentration of WA (10  $\mu$ mol/L) was used to show downregulation of ERBB2 (49). Overexpression of ERBB2 sensitized breast cancer cells to WA (49). Downstream effects included suppression of AKT by WA treatment (49). Increased phosphorylation of ribosomal S6 kinase (RSK) was also reported in breast cancer cells following WA treatment (25). RSK activation by WA led to activation of ETS-like transcription factor 1 and C-EBP homologous protein kinase pathways and subsequent upregulation of death receptor 5 to cause apoptotic cell death (25).

#### (G) Inhibitor of apoptosis (IAP) family members

The IAP family protein members regulate apoptosis by inhibiting caspases (89,90). Treatment with WA resulted in downregulation of XIAP, cIAP-2, and survivin protein levels in MCF-7 and MDA-MB-231 cells (66). Apoptosis induction by WA was attenuated by overexpression of XIAP, survivin, and cIAP-2 in both cell lines (66). Interestingly, the inhibition of MDA-MB-231 xenograft growth by WA administration was associated with statistically significant downregulation of only survivin protein expression (66). The *in vivo* role of the IAP family members in breast cancer prevention by WA is yet to be elucidated.

#### (H) Autophagy regulation proteins

The autophagy is an evolutionarily conserved process for re-cycling of cellular macromolecules as well as organelles like mitochondria (91). This process is tightly regulated by the members of the autophagy-related gene (ATG) family (91). Our laboratory was the first to demonstrate autophagy induction in MCF-7 and MDA-MB-231 cells following treatment with WA (92). However, this process is not cancer selective as autophagy induction by WA was also observed in the MCF-10A cell line (92). Inhibition of

MDA-MB-231 and MCF-7 cell viability resulting from WA treatment was not affected by either pharmacological suppression with 3-methyl adenine or genetic repression of ATG5 (92). Autophagy induction by WA in breast cancer cells was subsequently confirmed by other investigators (27,93).

## (I) Covalent modification of proteins

Because WA is an electrophile (Michael acceptor), it can directly react with cysteine residue(s) in different proteins. Bargagna-Mohan *et al* (94) were the first to demonstrate modification of cysteine-328 of vimentin protein by WA treatment (5  $\mu\text{mol/L}$ ) using endothelial cells. Subsequent work from our own laboratory showed covalent modification of cysteine-303 of  $\beta$ -tubulin following treatment of MCF-7 cells with 2  $\mu\text{mol/L}$  WA (53). In this study, we used NMR to demonstrate that the A-ring enone in WA was highly reactive with cysteamine (a nucleophile) and rapidly succumbed to irreversible nucleophilic addition (53). Molecular docking indicated that the WA-binding pocket was located on the surface of  $\beta$ -tubulin and characterized by a hydrophobic floor, a hydrophobic wall, and a charge-balanced hydrophilic entrance. These results provided novel insights into the mechanism of growth arrest by WA in breast cancer cells (53). Covalent modification of cysteine-179 of IKK $\beta$  after treatment of human embryonic kidney HEK293T cells with 5  $\mu\text{mol/L}$  WA was also reported as a mechanism of NF- $\kappa$ B inhibition (95). Using a synthetic NF- $\kappa$ B-p50 peptide, Gambhir *et al* (77) reported covalent modification of cysteine-62 residue. More recently, Grossman *et al* (96) used chemo-proteomic platforms to map the proteome-wide cysteine modification by WA. These investigators concluded that cysteine-377 on the regulatory subunit of the tumor-suppressor protein phosphatase 2A was a target of WA at least in the 231MFP cells line, which is a highly aggressive variant of the MDA-MB-231 human breast cancer cell line (96). However, other previously known modifications (e.g., vimentin,  $\beta$ -tubulin or IKK $\beta$ ) could not be validated in the study by Grossman *et al* (96), which also did not rule out the possibility of covalent modification of previously published targets under different experimental conditions. Pin1 protein has two cysteine residues at positions 57 and 113. Molecular docking suggested interaction of WA with cysteine-113 of Pin1 that was confirmed by mass spectrometry (54).

## Conclusions, future directions, and gaps in knowledge

Cancer cell selectivity, oral bioavailability, target tissue bioavailability, safety, and efficacy are desired characteristics for clinical development of a chemopreventive intervention. WA meets all these criteria based on preclinical studies discussed in this article. However, there are still critical knowledge gaps that need to be filled before clinical investigation of WA. First, the kinetics of mammary/tumor tissue bioavailability and clearance of WA is yet to be determined, which is essential for optimization of dosing schedule. Cellular *in vitro* studies indicate sensitivity of basal-like breast cancer cells to WA, but it is important to test whether development of this subtype of breast cancer is prevented by WA administration even though xenograft studies have shown *in vivo* therapeutic response of WA against basal-like human breast cancer cells. Cellular *in vitro* mechanistic studies have largely focused on luminal-type MCF-7 and basal-like MDA-MB-231 cells. Similar studies are needed in HER2-enriched breast cancer cell line like SK-BR-3 to broaden the mechanistic knowledge.

Although cell viability inhibition and mitotic arrest by WA has been reported in luminal, basal, and Her2-enriched breast cancer cells (53). Nevertheless, the pre-clinical results are quite compelling to advance WA to a phase 1 trial. A current limitation is that WA is not yet approved by the United States Food and Drug administration.

## Acknowledgement

Studies from the senior author's laboratory cited in this review article were supported by the US PHS grant CA142604, awarded by the national cancer Institute.

## References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin* 2020;70:7–30. [PubMed: 31912902]
2. Palliyaguru DL, Singh SV, Kensler TW. *Withania somnifera*: From prevention to treatment of cancer. *Mol Nutr Food Res*. 2016;60:1342–53. [PubMed: 26718910]
3. Azgomi RND, Zomorodi A, Nazemyieh H, Fazljou SMB, Bazargani SH, Nejatbakhsh F, et al. Effects of *Withania somnifera* on reproductive system: A systematic review of the available evidence. *Biomed Res Int* 2018;2018:4076430. [PubMed: 29670898]
4. Sarris J Herbal medicines in the treatment of psychiatric disorders: 10-year updated review. *Phytother Res* 2018;32:1147–62. [PubMed: 29575228]
5. Srivastav S, Fatima M, Mondal AC. Important medicinal herbs in Parkinson's disease pharmacotherapy. *Biomed Pharmacother* 2017;92:856–63. [PubMed: 28599249]
6. Tandon N, Yadav SS. Safety and clinical effectiveness of *Withania Somnifera* (Linn.) Dunal root in human ailments. *J Ethnopharmacol* 2020;255:112768. [PubMed: 32201301]
7. Saggam A, Tillu G, Dixit S, Chavan-Gautam P, Borse S, Joshi K, et al. *Withania somnifera* (L.) Dunal: A potential therapeutic adjuvant in cancer. *J Ethnopharmacol* 2020;255:112759. [PubMed: 32173425]
8. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. *Indian J Psychol Med* 2012;34:255–62. [PubMed: 23439798]
9. Agnihotri AP, Sontakke SD, Thawani VR, Saoji A, Goswami VS. Effects of *Withania somnifera* in patients of schizophrenia: a randomized, double blind, placebo controlled pilot trial study. *Indian J Pharmacol* 2013;45:417–8. [PubMed: 24014929]
10. Wankhede S, Langade D, Joshi K, Sinha SR, Bhattacharyya S. Examining the effect of *Withania somnifera* supplementation on muscle strength and recovery: a randomized controlled trial. *J Int Soc Sports Nutr* 2015;12:43. [PubMed: 26609282]
11. Choudhary D, Bhattacharyya S, Bose S. Efficacy and safety of Ashwagandha (*Withania somnifera* (L.) Dunal) root extract in improving memory and cognitive functions. *J Diet Suppl* 2017;14:599–612. [PubMed: 28471731]
12. Shohat B, Gitter S, Abraham A, Lavie D. Antitumor activity of withaferin A (NSC-101088). *Cancer Chemother Rep* 1967;51:271–6. [PubMed: 6062297]
13. Yang H, Shi G, Dou QP. The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry". *Mol Pharmacol* 2007;71:426–37. [PubMed: 17093135]
14. Srinivasan S, Ranga RS, Burikhanov R, Han SS, Chendil D. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. *Cancer Res* 2007;67:246–53. [PubMed: 17185378]
15. Stan SD, Hahm ER, Warin R, Singh SV. Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells *in vivo*. *Cancer Res* 2008;68:7661–9. [PubMed: 18794155]


16. Vyas AR, Singh SV. Molecular targets and mechanisms of cancer prevention and treatment by withaferin A, a naturally occurring steroidal lactone. *AAPS J* 2014;16:1–10. [PubMed: 24046237]
17. Cai Y, Sheng ZY, Chen Y, Bai C. Effect of Withaferin A on A549 cellular proliferation and apoptosis in non-small cell lung cancer. *Asian Pac J Cancer Prev* 2014;15:1711–4. [PubMed: 24641396]
18. Thaiparambil JT, Bender L, Ganesh T, Kline E, Patel P, Liu Y, et al. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. *Int J Cancer* 2011;129:2744–55. [PubMed: 21538350]
19. Patil D, Gautam M, Mishra S, Karupothula S, Gairola S, Jadhav S, et al. Determination of withaferin A and withanolide A in mice plasma using high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics after oral administration of *Withania somnifera* aqueous extract. *J Pharm Biomed Anal* 2013;80:203–12. [PubMed: 23584079]
20. Samanta SK, Sehrawat A, Kim SH, Hahm ER, Shuai Y, Roy R, et al. Disease subtype-independent biomarkers of breast cancer chemoprevention by the Ayurvedic medicine phytochemical Withaferin A. *J Natl Cancer Ins* 2016;109(6).
21. Dai T, Jiang W, Guo Z, Wang Z, Huang M, Zhong G, et al. Studies on oral bioavailability and first-pass metabolism of withaferin A in rats using LC-MS/MS and Q-TRAP. *Biomed Chromatogr* 2019;33:e4573. [PubMed: 31062367]
22. Wang F, Zhao J, Bai J, Gao K, Cui D, Chen Y, et al. Liquid chromatography-tandem mass spectrometry to assess the pharmacokinetics and tissue distribution of withaferin A in rats. *J Chromatogr B Analyt Technol Biomed Life Sci* 2019;1122–1123:90–5.
23. Pires N, Gota V, Gulia A, Hingorani L, Agarwal M, Puri A. Safety and pharmacokinetics of Withaferin-A in advanced stage high grade osteosarcoma: A phase I trial. *J Ayurveda Integr Med* 2020;11:68–72.
24. Sporn MB. Carcinogenesis and cancer: different perspectives on the same disease. *Cancer Res* 1991;51:6215–8. [PubMed: 1933881]
25. Nagalingam A, Kuppusamy P, Singh SV, Sharma D, Saxena NK. Mechanistic elucidation of the antitumor properties of withaferin A in breast cancer. *Cancer Res* 2014;74:2617–29. [PubMed: 24732433]
26. Kim SH, Hahm ER, Arlotti JA, Samanta SK, Moura MB, Thorne SH, et al. Withaferin A inhibits *in vivo* growth of breast cancer cells accelerated by Notch2 knockdown. *Breast Cancer Res Treat* 2016;157:41–54. [PubMed: 27097807]
27. Liu X, Li Y, Ma Q, Wang Y, Song AL. Withaferin-A inhibits growth of drug-resistant breast carcinoma by inducing apoptosis and autophagy, endogenous reactive oxygen species (ROS) production, and inhibition of cell migration and nuclear factor kappa B (Nf- $\kappa$ B)/mammalian target of rapamycin (m-TOR) signalling Pathway. *Med Sci Monit* 2019;25:6855–63. [PubMed: 31512681]
28. Sørli T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci USA* 2001;98:10869–74. [PubMed: 11553815]
29. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *J Natl Cancer Inst* 1998;90:1371–88. [PubMed: 9747868]
30. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial: Multiple outcomes of raloxifene evaluation. *Breast Cancer Res Treat* 2001;65:125–34. [PubMed: 11261828]
31. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. *N Eng J Med* 2011;364:2381–91.
32. Hahm ER, Lee J, Kim SH, Sehrawat A, Arlotti JA, Shiva SS, et al. Metabolic alterations in mammary cancer prevention by withaferin A in a clinically relevant mouse model. *J Natl Cancer Inst* 2013;105:1111–22. [PubMed: 23821767]

33. Thompson HJ, Adlakha H. Dose-responsive induction of mammary gland carcinomas by the intraperitoneal injection of 1-methyl-1-nitrosourea. *Cancer Res* 1991;51:3411–5. [PubMed: 2054781]
34. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ. Comparative study of human and rat mammary tumorigenesis. *Lab Invest* 1990;62:244–78. [PubMed: 2107367]
35. Chan MM, Lu X, Merchant FM, Iglehart JD, Miron PL. Gene expression profiling of NMU-induced rat mammary tumors: cross species comparison with human breast cancer. *Carcinogenesis* 2005;26:1343–53. [PubMed: 15845649]
36. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. *Cancer Res* 1987;47:4020–4. [PubMed: 3607747]
37. Lubet RA, Steele VE, Casebolt TL, Eto I, Kelloff GJ, Grubbs CJ. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. *Carcinogenesis* 1994;15:2775–80. [PubMed: 8001234]
38. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci USA* 2003;100:3983–8. [PubMed: 12629218]
39. Velasco-Velázquez MA, Homsí N, De La Fuente M, Pestell RG. Breast cancer stem cells. *Int J Biochem Cell Biol* 2012;44:573–7. [PubMed: 22249027]
40. O'Brien CS, Farnie G, Howell SJ, Clarke RB. Breast cancer stem cells and their role in resistance to endocrine therapy. *Horm Cancer* 2011;2:91–103. [PubMed: 21761332]
41. Kim SH, Singh SV. Mammary cancer chemoprevention by withaferin A is accompanied by *in vivo* suppression of self-renewal of cancer stem cells. *Cancer Prev Res (Phila)* 2014;7:738–47. [PubMed: 24824039]
42. Yang Z, Garcia A, Xu S, Powell DR, Vertino PM, Singh S, et al. *Withania somnifera* root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition. *PLoS One* 2013;8:e75069. [PubMed: 24069380]
43. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. *J Clin Oncol* 2010;28:3271–7. [PubMed: 20498394]
44. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100:57–70. [PubMed: 10647931]
45. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011;144:646–74. [PubMed: 21376230]
46. Zhang H, Samadi AK, Cohen MS, Timmermann BN. Anti-proliferative withanolides from the *Solanaceae*: a structure-activity study. *Pure Appl Chem* 2012;84:1353–67. [PubMed: 24098060]
47. Szarc vel Szic K, Op de Beeck K, Ratman D, Wouters A, Beck IM, Declerck K, et al. Pharmacological levels of Withaferin A (*Withania somnifera*) trigger clinically relevant anticancer effects specific to triple negative breast cancer cells. *PLoS One* 2014;9:e87850. [PubMed: 24498382]
48. Lu L, Shi W, Deshmukh RR, Long J, Cheng X, Ji W, et al. Tumor necrosis factor- $\alpha$  sensitizes breast cancer cells to natural products with proteasome-inhibitory activity leading to apoptosis. *PLoS One* 2014;9:e113783. [PubMed: 25419573]
49. Liu W, Barnette AR, Andreansky S, Landgraf R. ERBB2 overexpression establishes ERBB3-dependent hypersensitivity of breast cancer cells to withaferin A. *Mol Cancer Ther* 2016;15:2750–7. [PubMed: 27474152]
50. Hahm ER, Lee J, Huang Y, Singh SV. Withaferin a suppresses estrogen receptor- $\alpha$  expression in human breast cancer cells. *Mol Carcinog* 2011;50:614–24. [PubMed: 21432907]
51. Stan SD, Zeng Y, Singh SV. Ayurvedic medicine constituent withaferin A causes G<sub>2</sub> and M phase cell cycle arrest in human breast cancer cells. *Nutr Cancer* 2008;60(Suppl 1):51–60. [PubMed: 19003581]
52. Zhang X, Mukerji R, Samadi AK, Cohen MS. Down-regulation of estrogen receptor- $\alpha$  and rearranged during transfection tyrosine kinase is associated with withaferin A-induced apoptosis in MCF-7 breast cancer cells. *BMC Complement Altern Med* 2011;11:84. [PubMed: 21978374]
53. Antony ML, Lee J, Hahm ER, Kim SH, Marcus AI, Kumari V, et al. Growth arrest by the antitumor steroidal lactone withaferin A in human breast cancer cells is associated with down-


- regulation and covalent binding at cysteine 303 of  $\beta$ -tubulin. *J Biol Chem* 2014;289:1852–65. [PubMed: 24297176]
54. Samanta SK, Lee J, Hahm ER, Singh SV. Peptidyl-prolyl *cis/trans* isomerase Pin1 regulates withaferin A-mediated cell cycle arrest in human breast cancer cells. *Mol Carcinog* 2018;57:936–46. [PubMed: 29603395]
  55. Harris AL, Fox S, Leek R, Zhang H, Scott P, Bicknell R, et al. Breast cancer angiogenesis: therapy target and prognostic factor. *Eur J Cancer* 1995;31A:831–2. [PubMed: 7543767]
  56. Kumar A, Golani A, Kumar LD. EMT in breast cancer metastasis: an interplay of microRNAs, signaling pathways and circulating tumor cells. *Front Biosci (Landmark Ed)* 2020;25:979–1010. [PubMed: 32114421]
  57. Folkman J Tumor angiogenesis: therapeutic implications. *N Engl J Med* 285:1182–6.
  58. Lee J, Sehrawat A, Singh SV. Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells. *Breast Cancer Res Treat* 2012;136:45–56. [PubMed: 22965833]
  59. Lee J, Hahm ER, Marcus AI, Singh SV. Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level *in vivo* in breast tumors. *Mol Carcinog* 2015;54:417–29. [PubMed: 24293234]
  60. Mohan R, Hammers HJ, Bargagna-Mohan P, Zhan XH, Herbstritt CJ, Ruiz A, et al. Withaferin A is a potent inhibitor of angiogenesis. *Angiogenesis* 2004;7:115–22. [PubMed: 15516832]
  61. Awasthi P, Foiani M, Kumar A. ATM and ATR signaling at a glance. *J Cell Sci* 2015;128:4255–62. [PubMed: 26567218]
  62. Fokas E, Prevo R, Hammond EM, Brunner TB, McKenna WG, Muschel RJ. Targeting ATR in DNA damage response and cancer therapeutics. *Cancer Treat Rev* 2014;40:109–17. [PubMed: 23583268]
  63. Hahm ER, Lee J, Abella T, Singh SV. Withaferin A inhibits expression of ataxia telangiectasia and Rad3-related kinase and enhances sensitivity of human breast cancer cells to cisplatin. *Mol Carcinog* 2019;58:2139–48. [PubMed: 31441116]
  64. Hahm ER, Moura MB, Kelley EE, Van Houten B, Shiva S, Singh SV. Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. *PLoS One* 2011;6:e23354. [PubMed: 21853114]
  65. Zhang X, Timmermann B, Samadi AK, Cohen MS. Withaferin A induces proteasome-dependent degradation of breast cancer susceptibility gene 1 and heat shock factor 1 proteins in breast cancer cells. *ISRN Biochem* 2012;2012:707586. [PubMed: 25969759]
  66. Hahm ER, Singh SV. Withaferin A-induced apoptosis in human breast cancer cells is associated with suppression of inhibitor of apoptosis family protein expression. *Cancer Lett* 2013;334:101–8. [PubMed: 22935676]
  67. Hahm ER, Lee J, Singh SV. Role of mitogen-activated protein kinases and Mcl-1 in apoptosis induction by withaferin A in human breast cancer cells. *Mol Carcinog* 2014;53:907–16. [PubMed: 24019090]
  68. Ghosh K, De S, Das S, Mukherjee S, Sengupta Bandyopadhyay S. Withaferin A Induces ROS-Mediated Paraptosis in Human Breast Cancer Cell-Lines MCF-7 and MDA-MB-231. *PLoS One* 2016;11:e0168488. [PubMed: 28033383]
  69. Royston KJ, Udayakumar N, Lewis K, Tollefsbol TO. A novel combination of withaferin A and sulforaphane inhibits epigenetic machinery, cellular viability and induces apoptosis of breast cancer cells. *Int J Mol Sci* 2017;18:piiE1092.
  70. Sehrawat A, Samanta SK, Hahm ER, St Croix C, Watkins S, Singh SV. Withaferin A-mediated apoptosis in breast cancer cells is associated with alterations in mitochondrial dynamics. *Mitochondrion*. 2019;47:282–93. [PubMed: 30685490]
  71. Warburg O On respiratory impairment in cancer cells. *Science* 1956;124:269–70. [PubMed: 13351639]
  72. Dias AS, Almeida CR, Helguero LA, Duarte IF. Metabolic crosstalk in the breast cancer microenvironment. *Eur J Cancer* 2019;121:154–71. [PubMed: 31581056]
  73. Ogrodzinski MP, Bernard JJ, Lunt SY. Deciphering metabolic rewiring in breast cancer subtypes. *Transl Res* 2017;189:105–22. [PubMed: 28774752]

74. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. *Cancer J* 2010;16:348–53. [PubMed: 20693846]
75. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. *J Immunol* 2007;179:977–83. [PubMed: 17617589]
76. Sinha P, Ostrand-Rosenberg S. Myeloid-derived suppressor cell function is reduced by Withaferin A, a potent and abundant component of *Withania somnifera* root extract. *Cancer Immunol Immunother* 2013;62:1663–73. [PubMed: 23982485]
77. Gambhir L, Checker R, Sharma D, Thoh M, Patil A, Degani M, et al. Thiol dependent NF- $\kappa$ B suppression and inhibition of T-cell mediated adaptive immune responses by a naturally occurring steroidal lactone withaferin A. *Toxicol Appl Pharmacol* 2015;289:297–312. [PubMed: 26408225]
78. Malik F, Kumar A, Bhushan S, Mondhe DM, Pal HC, Sharma R, et al. Immune modulation and apoptosis induction: Two sides of antitumoural activity of a standardised herbal formulation of *Withania somnifera*. *Eur J Cancer* 2009;45:1494–509. [PubMed: 19269163]
79. Davis L, Kuttan G. Effect of *Withania somnifera* on cell mediated immune responses in mice. *J Exp Clin Cancer Res* 2002;21:585–90. [PubMed: 12636106]
80. Liu Y, Ao X, Ding W, Ponnusamy M, Wu W, Hao X, et al. Critical role of FOXO3a in carcinogenesis. *Mol Cancer* 2018;17:104. [PubMed: 30045773]
81. Ma JH, Qin L, Li X. Role of STAT3 signaling pathway in breast cancer. *Cell Commun Signal* 2020;18:33.
82. Lee J, Hahm ER, Singh SV. Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells. *Carcinogenesis* 2010;31:1991–8. [PubMed: 20724373]
83. Lamb CA, Vanzulli SI, Lanari C. Hormone receptors in breast cancer: more than estrogen receptors. *Medicina (B Aires)* 2019;79:540–5. [PubMed: 31864223]
84. Slee EA, O'Connor DJ, Lu X. To die or not to die: how does p53 decide? *Oncogene* 2004;23:2809–18. [PubMed: 15077144]
85. Jo M, Eastman BM, Webb DL, Stoletov K, Klemke R, Gonias SL. Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells. *Cancer Res* 2010;70:8948–58. [PubMed: 20940399]
86. Yu F, Li J, Chen H, Fu J, Ray S, Huang S, et al. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. *Oncogene* 2011;30:2161–72. [PubMed: 21242971]
87. Bhateja P, Cherian M, Majumder S, Ramaswamy B. The Hedgehog signaling pathway: A viable target in breast cancer? *Cancers (Basel)* 2019;11:1126.
88. Yoneyama T, Arai MA, Sadhu SK, Ahmed F, Ishibashi M. Hedgehog inhibitors from *Withania somnifera*. *Bioorg Med Chem Lett* 2015;25:3541–4. [PubMed: 26169123]
89. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. *Oncogene* 1998;17:3247–59. [PubMed: 9916987]
90. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome *c* by direct inhibition of distinct caspases. *EMBO J* 1998;17:2215–23. [PubMed: 9545235]
91. Romero MA, Bayraktar Ekmekcigil O, Bagca BG, Avci CB, Sabitaliyevich UY, Zhenisovna TG, et al. Role of autophagy in breast cancer development and progression: Opposite sides of the same coin. *Adv Exp Med Biol* 2019;1152:65–73. [PubMed: 31456180]
92. Hahm ER, Singh SV. Autophagy fails to alter withaferin A-mediated lethality in human breast cancer cells. *Curr Cancer Drug Targets* 2013;13:640–50. [PubMed: 23607597]
93. Muniraj N, Siddharth S, Nagalingam A, Walker A, Woo J, Gyorffy B, et al. Withaferin A inhibits lysosomal activity to block autophagic flux and induces apoptosis *via* energetic impairment in breast cancer cells. *Carcinogenesis* 2019;in press (doi: 10.1093/carcin/bgz015)
94. Bargagna-Mohan P, Paranthan RR, Hamza A, Dimova N, Trucchi B, Srinivasan C, et al. Mohan R. Withaferin A targets intermediate filaments glial fibrillary acidic protein and vimentin in a model of retinal gliosis. *J Biol Chem* 2010;285:7657–69. [PubMed: 20048155]

95. Heyninck K, Lahtela-Kakkonen M, Van der Veken P, Haegeman G, Vanden Berghe W. Withaferin A inhibits NF- $\kappa$ B activation by targeting cysteine 179 in IKK $\beta$ . *Biochem Pharmacol* 2014;91:501–9. [PubMed: 25159986]
96. Grossman EA, Ward CC, Spradlin JN, Bateman LA, Huffman TR, Miyamoto DK, et al. Covalent ligand discovery against druggable hotspots targeted by anti-cancer natural products. *Cell Chem Biol* 2017;24:1368–76. [PubMed: 28919038]
97. Ndlovu MN, Van Lint C, Van Wesemael K, et al. Hyperactivated NF- $\kappa$ B and AP-1 transcription factors promote highly accessible chromatin and constitutive transcription across the interleukin-6 gene promoter in metastatic breast cancer cells. *Mol Cell Biol*. 2009;29(20):5488–504. [PubMed: 19687301]
98. Sehrawat A, Singh SV. Short-form RON overexpression augments benzyl isothiocyanate-induced apoptosis in human breast cancer cells. *Mol Carcinog*. 2016;55(5):473–85. [PubMed: 25857724]
99. Piao L, Canguo Z, Wenjie L, Xiaoli C, Wenli S, Li L. Lipopolysaccharides-stimulated macrophage products enhance Withaferin A-induced apoptosis via activation of caspases and inhibition of NF- $\kappa$ B pathway in human cancer cells. *Mol Immunol*. 2017;81:92–101. [PubMed: 27915154]
100. Szarc Vel Szic K, Declerck K, Crans RAJ, et al. Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A. *Oncotarget*. 2017;8(25):40434–53. [PubMed: 28467815]
101. Ghosh K, De S, Mukherjee S, Das S, Ghosh AN, Sengupta SB. Withaferin A induced impaired autophagy and unfolded protein response in human breast cancer cell-lines MCF-7 and MDA-MB-231. *Toxicol In Vitro*. 2017;44:330–8. [PubMed: 28782635]



**Figure 1:**  
**A,** Cancer hallmarks affected by WA treatment in breast cancer cells *in vitro* and/or *in vivo*. This figure is modified based on revised cancer hallmarks reported by Hanahan D and Weinberg RA (45). **B,** mechanism underlying anticancer effect of WA in breast cancer cells.



**Figure 2:**

Inhibitory effects of WA on metabolic intermediates in breast cancer cells. The metabolite levels suppressed by WA are identified by red color whereas downregulation of proteins is shown in green color.

**Table 1:**

Pharmacokinetics of WA in mice and rats.

| dose / route        | Specimen      | $t_{1/2}$ (h) | $T_{max}$ (h) | $C_{max}$ ( $\mu$ M) | $AUC_{(0-t)}$ ( $\mu$ M·h) | Ref. |
|---------------------|---------------|---------------|---------------|----------------------|----------------------------|------|
| 4 mg/kg WA / i.p    | mouse plasma  | 1.3           | 0.083         | 1.8                  | 1.09                       | (18) |
| * 1 g/kg WSE / i.g. | mouse plasma  | 0.999         | 0.333         | 0.0355               | 0.056                      | (19) |
| 4.5 mg/kg WA / i.v. | rat plasma    | 0.93          | 0.33          | 0.062                | 0.060                      | (22) |
| 4.5 mg/kg WA / i.g. | rat plasma    | 1.15          | 0.86          | 0.046                | 0.052                      | (22) |
| 1.5 mg/kg WA / i.g. | rat plasma    | 0.78          | 1.03          | 0.031                | 0.035                      | (22) |
| 0.5 mg/kg WA / i.g. | rat plasma    | 1.00          | 0.97          | 0.013                | 0.025                      | (22) |
| 5 mg/kg WA / i.v.   | rat plasma    | 4.5           | —             | 6.477                | 7.682                      | (21) |
| 10 mg/kg WA / i.g.  | rat plasma    | 7.6           | 0.11          | 1.315                | 4.983                      | (21) |
| 4.5 mg/kg WA / i.g. | rat stomach   | 1.02          | 1.50          | 5.679                | 0.030                      | (22) |
| 4.5 mg/kg WA / i.g. | rat intestine | 3.21          | 1.80          | 2.826                | 0.025                      | (22) |
| 4.5 mg/kg WA / i.g. | rat heart     | 1.55          | 3.50          | 3.842                | 0.029                      | (22) |
| 4.5 mg/kg WA / i.g. | rat liver     | 0.95          | 3.00          | 1.990                | 0.018                      | (22) |
| 4.5 mg/kg WA / i.g. | rat lung      | 1.02          | 3.50          | 3.835                | 0.029                      | (22) |
| 4.5 mg/kg WA / i.g. | rat kidney    | 0.79          | 5.00          | 3.633                | 0.027                      | (22) |
| 4.5 mg/kg WA / i.g. | rat spleen    | 0.61          | 3.50          | 2.083                | 0.022                      | (22) |

\* WSE, aqueous extract of *Withaniasomnifera* (dosing equivalent to about 0.46 mg/kg WA).

i.p., intraperitoneal; i.g., oral; i.v., intravenous.

**Table 2:**

*In vivo* efficacy studies with withaferin A in preclinical models of breast cancer.

| Experimental model              | Dose       | Route | Outcome                                                  | Ref. |
|---------------------------------|------------|-------|----------------------------------------------------------|------|
| MDA-MB-231 xenograft            | 4 mg/kg    | i.p.  | Inhibition of tumor growth (therapy)                     | (15) |
| 4T1 xenograft                   | 4 mg/kg    | i.p.  | Inhibition of tumor growth and metastasis (therapy)      | (18) |
| MNU-rat model                   | 4,8 mg/kg  | i.p.  | Inhibition of tumor incidence (chemoprevention)          | (20) |
| MDA-MB-231 xenograft            | 4 mg/kg    | i.p.  | Inhibition of tumor growth (therapy)                     | (25) |
| MDA-MB-231 and SUM159 xenograft | 100 µg     | i.p.  | Inhibition of Notch2-promoted tumor growth (therapy)     | (26) |
| MDA-MB-231 xenograft            | 5-20 mg/kg | i.p.  | Inhibition of tumor growth (therapy)                     | (27) |
| MMTV- <i>neu</i> model          | 100 µg     | i.p.  | Inhibition of tumor progression (chemoprevention)        | (32) |
| MMTV- <i>neu</i> model          | 100 µg     | i.p.  | Inhibition of breast cancer stem cells (Chemoprevention) | (41) |
| MDA-MB-231 xenograft            | 1–8 mg/kg  | i.p.  | Inhibition of tumor growth and metastasis (therapy)      | (42) |

i.p., intraperitoneal.

**Table 3.**

Biological effects of withaferin A (WA) in breast cancer cell lines.

| Dose of WA ( $\mu\text{mol/L}$ ) | Cell line                                     | Biological effect                                                                                                          | Ref. |
|----------------------------------|-----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|------|
| 0.5–5                            | MCF-7, MDA-MB-231                             | Inhibition of growth and induction of apoptosis                                                                            | (15) |
| 0.027–2                          | MDA-MB-231                                    | Inhibition of cell invasion                                                                                                | (18) |
| 5                                | MCF-7, MDA-MB-231                             | Activation of ERK/RSK-DR5                                                                                                  | (25) |
| 0.25–1                           | MCF-7, SUM159                                 | Inhibition of breast cancer stemness                                                                                       | (41) |
| 0.7                              | MDA-MB-231                                    | Epigenetic effects                                                                                                         | (47) |
| 1–2.5                            | MDA-MB-231                                    | Synergistic apoptotic effect with TNF- $\alpha$                                                                            | (48) |
| 10                               | SK-BR-3, BT474, ERBB2 overexpressing MCF-7    | Role of ERBB2/ERBB3 in anti-proliferative effect                                                                           | (49) |
| 1.25–2.5                         | MCF-7, T47-D                                  | Inhibition of ER- $\alpha$ signaling                                                                                       | (50) |
| 0.5–2.5                          | MCF-7                                         | Downregulation of ER- $\alpha$                                                                                             | (52) |
| 2–4                              | MCF-7, SK-BR-3, SUM159                        | Downregulation and covalent binding of Cys303 of $\beta$ -Tubulin                                                          | (53) |
| 0.5–10                           | MCF-7, SK-BR-3                                | Inhibition of Pin1 and covalent binding to Cys113 of Pin1                                                                  | (54) |
| 1–4                              | MCF-7, MDA-MB-231, MDA-MB-468                 | Activation of Notch2 and Notch4                                                                                            | (58) |
| 2–4                              | MCF-7, MDA-MB-231, MCF-10A                    | Reversal of experimental EMT                                                                                               | (59) |
| 2.5–5                            | MCF-7, MDA-MB-231                             | ROS-mediated apoptosis                                                                                                     | (64) |
| 0.25–2.5                         | MDA-MB-231, BT-20                             | Proteasome-dependent degradation of BRCA1 and HSF1                                                                         | (65) |
| 2.5–5                            | MCF-7, MDA-MB-231                             | Suppression of IAP family proteins                                                                                         | (66) |
| 1–5                              | MCF-7, SUM159                                 | Role of mitogen-activated protein kinases and Mcl-1 in apoptosis induction                                                 | (67) |
| 4                                | MCF-7, MDA-MB-231                             | ROS-mediated paraptosis                                                                                                    | (68) |
| 2–4                              | MCF-7, MDA-MB-231                             | Inhibition of mitochondrial dynamics and apoptosis induction                                                               | (70) |
| 2                                | MCF-7, MDA-MB-231                             | Induction of autophagy                                                                                                     | (92) |
| 2.5–5                            | MCF-7, MDA-MB-231, MDA-MB-468, SUM149, SUM159 | Inhibition of lysosomal activity leading to energy insufficiency and subsequent growth suppression and apoptosis induction | (93) |
| 10                               | 231MFP                                        | Covalent interaction with Cys377 of PPP2R1A and activation of PP2A activity                                                | (96) |